Use of peptide acth (4-7) -pgp of hepatoprotective action

FIELD: biotechnology.

SUBSTANCE: hepatoprotector is used as peptide ACTH (4-7) -PGP (Semax) having the formula Met-Glu-His-Phe-Pro-Gly-Pro.

EFFECT: use of the said peptide with the aim of hepatoprotection under condition of the development of free-radical oxidation of hepatocytes enables to improve the efficiency of treatment of liver diseases accompanied by intensification of free radical oxidation processes.

1 tbl, 1 ex


The invention relates to medicine, namely to Hepatology, physiology, pathophysiology, and can be used for hepatoprotective effects.

It is known that in the body as a result of redox reactions constantly leads to the formation of reactive oxygen species (ROS), with high reactivity and catalytic processes of free radical oxidation of biomolecules.

In terms of the norms of free radicals play an important role in the vital processes of cells in various biological systems, participating in oxidative phosphorylation, the biosynthesis of prostaglandins and nucleic acids in the regulation of lipid metabolism, etc. But their role in biological systems are very dynamic, because free radicals are classified vysokoriskovannyh molecules, excessive formation which can quickly lead to disruption of cellular structures, disturbance of the functional activity of cells (Chesnokova N.P., Poucelina E.V., Lisenkova mathematical SCIENCES. Sources of free radicals and their importance in biological systems in terms of the norm // Modern high technologies. - 2006, №6. - P.28-34; VG Zaytsev, Zakrevsky VI Methodological aspects of the study of free radical oxidation and antioxidant system of the body // In the party Volgograd medical Academy. - 1998, T 4. 49-53. Mayansky, D.N. The problem of chronic inflammation in the modern pathophysiology // Pathol. Fiziol. and experimental. therapy. - 1994. No. 2. - P.51-55).

The toxic effect of ROS is prevented due to the functioning of antioxidant protection, presents the enzymatic and non-enzymatic components (Dubinin E.E. Role of reactive oxygen species as signaling molecules in tissue metabolism under oxidative stress // Questions of medical chemistry. - 2001, T, No. 6. - S-581). One of the first lines of defense cells from aggressive free radicals provide superoxide dismutase (SOD) and catalase, showing its activity in almost all cells of the human body, especially the liver, kidney, erythrocytes (Chesnokova N.P., Poucelina E.V., Lisenkova mathematical SCIENCES. Molecular and cellular mechanisms of inactivation of free radicals in biological systems // Successes of modern natural science. - 2006, No. 7. - P.29-36).

The liver as the most multifunctional organ belongs to a unique role in the regulation of the constancy of the internal environment of the body, has a high sensitivity to irritants (Zelikman O. Hepatotropic effects and monooxygenase system of the liver in chronic stress // Bulletin of the South Ural state University. - 2006, No. 3. S-122; skorupi VA Ultrastructure of liver cells p and stress. - Novosibirsk: Nauka, 1989. - 143 C.). Given the crucial role of the liver in homeostasis, this circumstance can adversely affect the health of other organs and systems.

In turn, the activation of free-radical oxidation processes underlies the pathogenesis of many diseases of the liver: nonalcoholic of steatohepatitis, viral diseases, and others, and the severity and prognosis of the disease is closely associated with the functional status of the antioxidant system of hepatocytes (Mesnjankina O.A., Naumov old Testament, Degtyarev O.V., Dujko CENTURIES of Free radical processes in the pathology of the liver in the elderly. Health organization Astrakhan medical journal. - 2011, No. 3. - P.39-43; breverb S.A. Oxidative stress and its role in liver damage // ROS. Journe. gastroenter., heat. and coloproctol. - 2002, No. 4. P.21-25).

This suggests that pharmacological agents that can activate the antioxidant enzymes must possess hepatoprotective properties (Ivanov Y., Matyushin I.A., Mishnev OD and other Effect of Mexidol in toxic liver damage // Bulletin of new medical technologies: the periodic theoretical and scientific-practical journal. - 2003. No. 3. - S-70).

Hepatoprotectors - drugs, improves metabolic processes in the liver, increasing its ostoich the stability to pathogenic influences, as well as contributing to the restoration of its functions under different damage (Karkishchenko NN. Clinical and environmental pharmacology terms and concepts. ): IMP-Medicine, 1995. - 304 S.).

Semax is heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro)obtained by synthetic analogue of a fragment 4-7 adrenocorticotropic hormone (ACTH), devoid of hormonal activity. He belongs to the group of cells with adaptive, analgesic and neuroprotective effects (Manchenko D.M., Glazov POSTGRADUATE, Levitskaya N.G. and other Neuroprotective and analgesic effects of Semax in various ways. - 2010. T, No. 10. - S-1023; Ivanov, D.M., Levitskaya N., Andreeva L.A. and other Comparative study of analgesic activity of a fragment of ACTH 4-10 and its analogue Semax // bul. the experimental. Biol. and medicine. - 2007, CH, No. 1. P.8-12).

Semax has antihypoxic effect (Ashmarin I.P., Nezavisimaya V.N., Meat eaters NF and other Nootropic similar adrenocorticotropin 4-10 - Semax (15-years experience of development and learning) // Ukr. the Supreme. a nerve. activity them. I.P. Pavlova. - 1997 T, No. 2. S-430; Levitskaya N.G., Sebentsov E.A., Andreeva L.A. and other Neuroprotective effects of Semax on the background of MPTP-induced disorders of the dopaminergic system of the brain // ROS. Fiziol. Journe. them. I.M. Sechenov. - 2002, T, No. 11. S-1377; Sebentsov E.A., Levitskaya N., Andreeva L.A. and other Effects this is KSA amid blockade of dopaminergic receptors by haloperidol // bul. the experimental. Biol. and medicine. - 2006, T, No. 2. S-132).

Semax administration has a stress-limiting effect on macrophage-proliferative and destructive processes in functionally-active zones of the spleen and limpidly plaques of the small intestine, inguinal lymph nodes, reduces stress-induced condition of the cells of the lymphoid series in peripheral blood (bachmat A.A. the Influence of some oligopeptides on the immune structure of lymphoid plaques small intestine // ROS. Journe. gastroenter., heat. and coloproctol. - 2008, No. 5. Ñ.38-44; bachmat A.A., Koplik E.V. anti-stress effect of Semax in the dynamics of recovery of lymphoid formations spleen after stress in rats with different behavioral activity // bul. exeem. Biol. and the honey. - 2012, T, No. 5. S-617; bachmat A.A. Morphological features of lymphoid structures of the inguinal lymph nodes of rats under emotional stress with the preliminary introduction of some oligopeptides // Saratov scientific medical journal. - 2009, Volume 5, No. 4. S-497).

Pepcid has anti-inflammatory effect (Gusev E.I., V.I. Skvortsova cerebral Ischemia. - M.: Medicine, 2001. 328 S.); able to prevent the increased generation of nitric oxide through the ischemic brain (Fadukova PU Semax prevents the increase of the generation of nitric oxide in the rat brain, due to incomplete Globa who enoy ischemia // Experiment. and the wedge. Pharmacol. - 2001, №64 (2). Pp.31-34).

In addition, the peptide ACTH (4-7)-GWP increases anticoagulant, total and non-enzymatic fibrinolytic activity, the activity of plasminogen activator in blood plasma of rats in conditions of immobilization stress (Ashmarin I.P., Lyapina L.A., Pastorova VE Modulation hemostatic reactions in vitro and in vivo representatives of the families of regulatory peptides, " Vestn. The RAMS. - 1996, No. 6. P.50-58; Grigorieva M.E. Ter-Minassian, Lyapina L.A. Anticoagulation and antiplatelet effects of the drug "Semax" in conditions of acute and chronic immobilization stress, Byull. experiment. Biol. and the honey. - 2010, CH, No. 1. 49-52), shows the antiaggregatory effects on platelets and reduces the level of heparin (Lyapina L.A., Pastorova V.E., Bergan T.U. Functional state of the anticoagulation system when exposed to a body of regulatory peptide Pro-Gly, Pro-Gly-Pro, the peptide and taphrina in connection with the natural heparin // Narkie. - 2008, V.25, No. 1-2. P.23-29); in norm increases the resistance of erythrocytes to hemolysis and reduces the interaction of red blood cells platelets, and in the conditions of immobilization stress without changing the rate of hemolysis, enhances the stability of erythrocytes (Golubeva MG Neuropeptide Semax alters the functional activity of erythrocytes and platelets in immobilization stress // Thrombosis,hemostasis and rheology. - 2010, No. 2. P.45-49).

The peptide increases the homeostasis of the gastric mucosa to the ulcerogenic action of such factors as ethanol and stress (Bakaeva ZINAIDA, Balikova CE, Klimov P.A. Mapping gastroprotective properties of Semax and its metabolites // Bulletin of Moscow University. Series 16: Biology. - 2009, issue 4. P.3-7).

However, the use of peptide ACTH (4-7)-GWP as hepatoprotector unknown.

The technical result is the new usage of the peptide ACTH (4-7)-GWP having the formula Met-Glu-His-Phe-Pro-Gly-Pro for the hepatoprotective effects.

The technical result is achieved by applying peptide ACTH (4-7)-GWP having the formula Met-Glu-His-Phe-Pro-Gly-Pro for the hepatoprotective effects. At the present time, because the known exact chemical formula of the peptide, it can be synthesized in any laboratory synthesis of peptides. The authors have used the drug, synthesized Russian cardiology research and production complex.

Dissolved in isotonic sodium chloride peptide ACTH (4-7)-GWP introduce experimental animals (rats) parenteral (intraperitoneal) in the dose of 5 and 50 mg/kg of body weight once a day for 5 days.

Specific example

Experimental animals (rats male Wistar) weighing 250-300 g were divided into group what s in 11 animals each (table). The animals were kept at the temperature of the air in the room at 22-24°C, light mode: 12 hours light, 12 hours dark, and received a standard pelleted food and water freely available in compliance with all regulations and International recommendations of the European Convention for the protection of vertebrate animals used in experimental research (1997), "Manual on experimental (preclinical) study of new pharmacological substances" (Moscow, 2005). At the time of the experiments the animals were healthy, changes in behavior, appetite, sleep and wakefulness are not detected.

Dissolved in isotonic sodium chloride to obtain the necessary doses of 5 and 50 mg/kg of body weight peptide ACTH (4-7)-PCP was administered to the experimental animal parenteral (intraperitoneal) once a day for 5 days. Control group animals received equivalent volumes of saline.

On the 5th day of the animals taken out of the experiment by exsanguination under ether anesthesia. A portion of liver was placed in cold saline and homogenized, followed by freezing at -20°C.

The functional state of the element of the antioxidant enzyme system of the liver was assessed by the content of superoxide dismutase (SOD) (Kostyuk V.A., A.N. Potapov, Kovalev IV // the honey. chemistry. 1990. No. 2. P.88-91) and catalase (Korolyuk M.A., Ivanova L.I., Mayorova I.G., Tokarev V.E. // lab. case. 1988. No. 1. P.16-19).

Statistical processing of results was made using t-student criterion and criterion of Mann-Whitney.

The experiments showed that after injection of peptide ACTH (4-7)-PCP at doses of 5 and 50 mg/kg activated element of the antioxidant enzyme system of the liver, indicating the hepatoprotective effect (table).

The status element of the antioxidant enzyme system of the liver in norm and in the conditions of introduction of the peptide ACTH (4-7)-GWP.
The group of animals
Control animalsIntroduction ACTH 4-7-PCP at a dose of 5 ág/kgIntroduction ACTH 4-7-PCP at a dose of 50 mg/kg
SOD, srvc. ed2,3±0,12,6±0,1*2,7±0,1*
Catalase, mkat/l4,8±0,25,8±0,3*5,6±0,3*
Note: * - p<0,05 in comparison with displaying the firs control group...

Thus, the results of experimental studies show that the use of the peptide ACTH (4-7)-PCP at doses of 5 and 50 mg/kg causes a hepatoprotective effect in animals in good condition. This method is based on application of regulatory peptide belonging to the class of biologically active substances with a strong modulatory effect and multifunctional, is not time consuming and does not require sophisticated equipment.

The use of peptide ACTH (4-7)-GWP having the formula Met-Glu-His-Phe-Pro-Gly-Pro, for the hepatoprotective effects.


Same patents:

FIELD: biotechnologies.

SUBSTANCE: composition for improvement of brain function as active ingredient includes peptide X-Pro-Pro-Leu-Thr-Gln-Thr-Pro-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu-Y (where X is absent or represents He or Asn-Ile; and Y is absent or represents Val-Met), peptide X-Val-Val-Val-Pro-Pro-Phe-Leu-Gln-Pro-Glu-Y (where X is absent or represents Thr-Gln-Thr-Pro, Pro-Leu-Thr-Gln-Thr-Pro, Leu-Thr-Gln-Thr-Pro or Pro; and Y is absent or represents Val-Met) or their salts. Method for improvement of brain function involves introduction of the above peptide or its salt.

EFFECT: invention allows effective prevention of amnesia and strengthening of memory at peroral use of a low dose of the above peptides.

35 cl, 6 dwg, 6 ex

FIELD: organic chemistry, antibiotics, medicine, oncology.

SUBSTANCE: invention relates to novel derivatives of aplidine possessing anti-tumor activity and represented by the general formula:

EFFECT: valuable medicinal property of compound, improved methods of synthesis and preparing.

28 cl, 3 tbl, 121 ex

FIELD: organic chemistry, chemistry of peptides.

SUBSTANCE: invention proposes derivative of kahalalide F that is not a mixture of isomers known as kahalalide F wherein a derivative has structure comprising a cyclic moiety and by-side chain and prepared from the formula (I): . This derivative differs from the formula (I) by one or more of the following features: 1-2 amino acids that are not identical with that's as amino acids in the structural formula (I); absence of one or two amino acids in by-side chain of the structural formula (I); 1-10 additional methylene groups in acyl group of the by-side chain of the structural formula (I); 1-5 methylene groups that are absent in acyl group of the by-side chain of the structural formula (I); 1-3 substitutes added to acyl group of the by-side chain of the structural formula (I); 5-methyl-substitute that is absent in acyl group of the by-side chain, and absence of acyl group of the by-side chain.

EFFECT: new structure of compound.

12 cl, 5 tbl, 60 ex

The invention relates to molecular biology and genetic engineering and can be used for biomedical research and biotechnological production of recombinant proteins by secretion by bacterial cells

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a new compound of formula [I] or to its pharmaceutically acceptable salt, wherein A represents optionally substituted alkyl, wherein the substitute represents identical or different 1-3 groups specified in aryl optionally substituted by 1-3 groups specified in alkyl, halogen, alkoxy and alkanoyl; cycloalkyl optionally substituted by 1-3 groups specified in alkyl and halogen; hydroxy; alkoxy; halogen; an amino group and oxo; an optionally substituted carbocyclic group specified in a mono- and bicyclic group, wherein an aromatic ring and cycloalkyl are condensed; optionally substituted aryl, an optionally substituted completely saturated 5- or 6-merous monocyclic heterocyclic group each of which contains 1 heteroatom specified in nitrogen and oxygen, wherein the substitute of optionally substituted aryl, the optionally substituted carbocyclic group and the optionally substituted heterocyclic group for A represents identical or different 1-3 groups specified in alkyl, optionally substituted hydroxy, alkoxy, cycloalkyl or halogen; cycloalkyl optionally substituted by alkyl or alkoxy; alkoxy optionally substituted by halogen; halogen; hydroxy; oxo; heterocycle; alkyl sulphonyl; and mono- or dialkylcarbamoyl, optionally substituted amino, wherein the substitute represents identical or different 1 or 2 alkyl or aryl, or optionally substituted carbamoyl, wherein the substitute represents identical or different 1 or 2 alkyls optionally substituted by aryl, X represents optionally substituted methylene or -O-, wherein the substitute of optionally substituted methylene for X represents alkoxy or hydroxy, Q represents N or C-R4, L1 represents a single bond, methylene, -CH=CH-, -O-, -CO-, -NR11-, -NR11CO-, -CONR11- or -CH2NR11-, L2 represents a single bond, -CR6R7- or a bivalent 5- or 6-merous completely saturated monocyclic heterocyclic group each of which contains 1 heteroatom specified in nitrogen and oxygen, R1 and R2 are identical or different, and each represents hydrogen, alkyl or halogen, R3 and R4 are identical or different, and each represents hydrogen, alkyl, alkoxy, cyano or halogen, R1 and R3 are optionally bond thereby forming 5- or 6-merous cycloalkane, or a 5- or 6-merous aliphatic heterocycle containing oxygen atom, R5 represents a carboxyl group, an alkoxycarbonyl group or a bioisosteric group of the carboxyl group, R6 and R7 are identical or different, and each represents hydrogen or alkyl, or R6 and R7 are bond thereby forming cycloalkane, R8 represents hydroxy, alkanoylamino or alkyl sulphonylamino, R9 and R10 represent hydrogen or halogen, and R11 represents hydrogen or alkyl. Besides, the invention refers to specific compounds of formula [I], a drug based on the compound of formula [I], using the compound of formula [I], a method of treating based on using the compound of formula [I], and an intermediate compound of formula [II].

EFFECT: there are prepared new compounds possessing the agonist activity on thyroid hormone β receptor.

18 cl, 36 tbl, 344 ex

FIELD: medicine.

SUBSTANCE: managing pregnancy in females suffering from overweight on their 26-30 weeks of pregnancy involves measuring an S-wave velocity in the hepatic tissue by acoustic pulse-wave elastometry. If an average value is 1.41 ms or more, hepatic protectors are administered.

EFFECT: reducing a rate of obstetric complications in the pregnant women suffering from overweight.

3 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises complex pathogenetic therapy. Additionally, the specific biological preparation is used. The preparation is prepared according to the principle of production of cytotoxic serum from donor blood by hyperimmunisation of their antigens prepared from liver and spleen tissue. The antihepatotoxic serum and serum antisplenotoxic serum are obtained. They are mixed with sterile saline solution preserved with phenol to 0.5% concentration on the basis of the content in 1.0 ml of 0.9-1.15 its titrated units of antihepatotoxic and antisplenotoxic sera by reaction of binding the complement. The preparation is administered to animals once subcutaneously in the area of the withers at a dose of 0.45-1.1 ml per 1 kg of live weight. The method provides a higher immune status of the animal organism and high efficacy of treatment.

EFFECT: invention enables to improve the efficiency of treatment of liver steatosis in cats.

4 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a therapeutic agent for preventing and treating chronic liver diseases. The above agent represents amaranth oil prepared by cold pressing of amaranth seed kernels and coats, to be used in a dose of 62.5 - 250 mg/kg of body weight.

EFFECT: declared invention provides higher positive effect on biochemical processes in blood and liver tissues in treating toxic hepatitis.

2 tbl

FIELD: medicine.

SUBSTANCE: method involves simulating hepatitis by 7-day alcoholisation in female rats. A hepatoprotective agent is presented by an api-phytocomposition in the form of an aqueous suspension of honey, lecithin and licorice root extract in the ratio of 10:2:1. The composition is introduced twice a day intragastrically before feeding in a dose of 200 mg/kg of body weight 5 days before ethanol introduction and for 7 days one hour before ethanol introduction.

EFFECT: effective treatment of hepatitis with no side effects.

1 ex, 1 tbl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to a pharmaceutical, dietary, nutritional orally soluble composition for peroral intake, which contains at least one S-adenosylmethyonine (SAMe) salt in a combination with physiologically acceptable excipients and optionally other active ingredients. The physiologically acceptable excipients include light magnesium oxide.

EFFECT: compositions of the claimed invention have high taste qualities, which provides easier peroral introduction The compositions by the invention are characterised by the higher systemic bioavailability of S-adenosylmethyonine.

15 cl, 2 dwg, 13 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the field of pharmaceutics. An extract of Fraxinus excelsior seeds, capable of activating PPAR-alpha, which contains nuzhenide GI3, oleoside methyl ester, excelside B, GI5, salidroside, in effective quantities. An application of the extract of Fraxinus excelsior seeds to obtain a medication for treating a state, in which the PPAR-alpha activation is useful, is described. Also described is a method of treating a subject with the state, in which the PPAR-alpha activation is useful. A method of obtaining the extract of Fraxinus excelsior seeds is disclosed.

EFFECT: application of the claimed extract makes it possible to treat states, in which the PPAR-alpha activation is useful in an efficient way.

14 cl, 11 dwg, 2 tbl, 13 ex

FIELD: medicine.

SUBSTANCE: viral hepatitis in simulated in laboratory animals (rats) with D-galactosamine. Hepatitis is treated by single oral administration of immobilised hyaluronidase 25 unit/kg. Administration either precedes simulation, or is combined with the beginning of stimulation.

EFFECT: method enables reducing a severity of metabolic and morphological hepatic disorders effectively in stimulating hepatitis identical to viral hepatitis in a human with underlying reduced xenobiotic load on the body.

1 ex, 3 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula II, methods of producing a compound of formula I

and formula II


a pharmaceutical composition and versions of use for treating inflammation and/or liver damage. In the compound of formula II, R1 is H; R2 is a linear or branched C1-C18alkoxy; C-18 is in an α-configuration.

EFFECT: high efficiency of the method.

18 cl, 7 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry, namely to a method of obtaining a preparation, possessing a hepatoprotective action. The method of obtaining the preparation, possessing the hepatoprotective action consists in extraction of crushed corn styles with stigmas with ethyl alcohol by a method of multi-step countercurrent extraction with completed cycle in a battery of 5 diffusers, a waste raw material is additionally extracted in 4 and 5 diffusers with an applied extractant, after which it is poured out and passed through 5 diffuser, and kept for a specified time; then, the waste raw material is pressed, the combined extract is settled, the purified extract is condensed under vacuum, dried in a vacuum oven until the dry extract is obtained and crushed under specified conditions.

EFFECT: method is effective for obtaining a stable preparation with the expressed hepatoprotective action.

14 dwg

FIELD: chemistry.

SUBSTANCE: radiopharmaceutical agent of formula (Ia) or (Ib) , is a cyclic octapeptide complex which contains a chelating group with radionuclides 111In, 90Y, 177Lu. The radiopharmaceutical agent can be used to produce medicinal agents for radionuclide therapy of neoplasms which express somatostatin receptors. X is a chelating agent.

EFFECT: improved properties.

2 cl, 1 dwg, 2 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to field of pharmaceutics and medicine and deals with pharmaceutical composition with delayed release, which contains as active ingredient octreotide or its pharmaceutically acceptable salt and two different linear copolymers of polylactide and glycolide (LCPG), characterised by molar ratios lactide/glycolide 75:25 and different values of viscosity, for prolonged supportive treatment of patients with acromegaly and for treatment of severe forms of diarrhoea and hyperaemia, associated with malignant carcinoid tumours and tumours, cells of which produce vasoactive intestinal peptide.

EFFECT: group of inventions ensure stably high level and fast achievement of required level of impact of active substance.

10 cl, 5 ex, 3 tbl, 1 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to peptides, isolated from human basic proline-rich lacrimal protein (BPLP), in particular to opiorphin, and is intended for application in manufacturing medication for treatment or prevention of such disease as obsessive-compulsive disorder, narcolepsy, hypersomnia, reduction of vigilance, deficit of attention in children, bipolar disease, dysthymic disorder and cyclothymic disorder.

EFFECT: application of group of inventions ensures application of peptides, which do not have at all or have very weak side effects.

15 cl, 3 dwg, 6 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: in the process of preoperative preparation imunofan is introduced to a patient intramuscularly in a dose of 1 ml one time per day. After that, laparoscopy with revision of the abdominal cavity organs, opening of the omental bursa and its washing with solutions of antiseptics, and formation of the external cholecystoma are performed. Intraoperatively at the stage of the omental bursa drainage and before performing cholecyctomy, into the stomach introduced is a thin probe for enteral nutrition, through which early intraoperative nutrition is realised by introduction of liquid food "Diason" at a rate of 30 ml/hour in an amount of 450-500 ml on the first day of the postoperative period. In the postoperative period introduction of imunofan in the same dose is continued for 9 days. Introduction of "Diason" food through the thin probe is also continued on the second day of the postoperative period at a rate of 30 ml/hour in an amount of 450-500 ml, on the third day at a rate of 45-60 ml/hour in an amount of 700-750 ml, on 4 and 5 day at a rate of 80-90 ml/hour in an amount of 950-1000 ml, from 6 to 9 days at a rate of 125-150 ml/hour in an amount of 1500-2000 ml. On the 10-th day after operation the probe of enteral nutrition is removed. After that, a seeping type of nutrition is realised, in the process of which a drink supportan or nutridrink is introduced to the patient in an amount of 200 ml 3-4 times per day until complete recovery of the trophological status.

EFFECT: method provides prophylaxis of purulent-inflammatory complications due to the prevention of impairment of cellular and humoral immunity and sufficient correction of the trophological status, contributing to a considerable increase of life quality of the operated patient.

3 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and concerns using a peptide conjugated with a protein representing a keyhole limpet hemocyanin (KLH) protein used as an immunogen for preparing antibodies specifically recognising any of prevailing versions of beta-amyloid peptide Aβ40 and Aβ42; or using an antibody, or an active fragment, or an antibody derivative of the above peptide in preparing a therapeutic agent for preventing and/or treating a disease characterised by amyloid accumulation in the patient's brain.

EFFECT: group of inventions provides effective immunisation, reduces an amyloid load and a quantity of brain amyloid plaques.

5 cl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a peptide represented by the formula (I) X1-Leu-X2-Leu-X3, where X1 is Glu or Asp, X2 is His, Lys or Arg, X3 is Asp or Glu, at that Glu, Asp, Leu, His, Lys and Arg, or its pharmaceutically acceptable salt and its compositions for treatment or prevention of cartilage damage and/or arthritis.

EFFECT: proposed peptide can affect the regeneration of cartilage tissue, inhibition of expression of the enzyme causing cartilage tissue matrix degradation, or inhibition of chondrosteosis.

7 cl, 2 tbl, 11 dwg, 15 ex